LYEL

Lyell Immunopharma, Inc. (LYEL) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Lyell Immunopharma is a late-stage clinical cell therapy company focused on developing autologous CAR T-cell therapies for hematologic malignancies and solid tumors. The company operates as a non-accelerated filer and smaller reporting company. As of August 3, 2026, there were 24,505,141 shares of common stock outstanding.

Key Financial Metrics

Note: All figures in thousands unless otherwise noted. Revenue is nominal, derived from sublease income and other non-product sources.

Material Changes vs. Prior Period

• Net Loss Reduction: The net loss for the six months ended June 30, 2026, decreased by $26.0 million compared to the same period in 2025. This improvement was primarily driven by a $17.6 million gain from the settlement of the Securities Purchase Agreement (SPA) put/call option in March 2026.
• Operating Expenses: Total operating expenses decreased by $12.9 million year-over-year for the six-month period. This was due to reduced personnel and facility costs following the successful technology transfer of the lead product (ronde-cel) to the LyFE Manufacturing Center in 2025, partially offset by increased clinical trial activity.
• Financing Activity: The company raised approximately $50.0 million in March 2026 through the Milestone Closing of the SPA and an additional $1.7 million via at-the-market offerings during the first half of 2026.
• Acquisitions: In November 2025, the company acquired exclusive global rights (outside mainland China) to LYL273, a GCC-targeted CAR T-cell candidate for colorectal cancer, involving an upfront payment of $40 million and equity issuance.

Guidance, Outlook, and Risks

• Clinical Pipeline:
  • Ronde-cel (CD19/CD20 CAR T): Two pivotal trials are underway: PiNACLE (3L+ setting) with data expected in H2 2026 and pivotal data in mid-2027; and PiNACLE-H2H (2L setting head-to-head), which commenced dosing in February 2026.
  • LYL273 (GCC-targeted CAR T): Phase 1 trial in mCRC showed a 67% overall response rate at the highest dose level. The protocol was amended to enable expansion into a potential pivotal Phase 2 trial.
• Liquidity: Management believes existing cash, cash equivalents, and marketable securities ($228.0 million) are sufficient to fund operations for at least the next 12 months. However, the company expects to incur significant losses for the foreseeable future and will require additional capital to complete development and commercialization.
• Risks:
  • Regulatory & Clinical: Failure of clinical trials to demonstrate safety/efficacy, delays in enrollment, or inability to obtain regulatory approval.
  • Manufacturing: Complexity of cell therapy manufacturing and reliance on the LyFE facility; potential supply chain disruptions.
  • Financial: Need for future capital raises which may result in dilution; volatility in fair value of success payment liabilities (Fred Hutch and Stanford agreements).
  • Macro: Impact of tariffs, inflation, and geopolitical conflicts on supply chains and costs.

Investor Verification Checklist

• Verify the timeline and enrollment status of the PiNACLE-H2H head-to-head trial, as this is a critical differentiator against approved competitors (axi-cel, liso-cel).
• Confirm the sufficiency of the $228 million cash balance against the projected burn rate, given the high costs of pivotal trials and the recent acquisition of LYL273.
• Review the terms of the success payment liabilities with Fred Hutch and Stanford, as changes in stock price could materially impact future earnings.
• Assess the progress of the LYL273 Phase 1/2 expansion and the safety profile regarding gastrointestinal toxicity, which previously required prophylaxis adjustments.
• Monitor the manufacturing capacity at the LyFE facility to ensure it can support both ronde-cel and LYL273 clinical and potential commercial needs.